# GPT 5.2 Review - Round 4/10

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-18T19:10:44.418888
**Response ID:** resp_0710fd6ca3cfc2d300696d2170e1588194916e8d709d870158
**Tokens:** 15815 in / 7820 out
**Response SHA256:** 1ccc52d18dc94bc2

---

## Referee Report (AER/QJE/Econometrica standard)

Paper: *“The Montana Miracle Revisited: Early Evidence on the Effects of Statewide Zoning Reform on Residential Construction”* (APEP, Jan 2026)

### Summary
The paper evaluates Montana’s 2023 zoning reforms (ADU legalization statewide; duplex legalization in qualifying municipalities) using (i) a state-level TWFE DiD against five “Mountain West” controls and (ii) a synthetic control using (apparently) 47 donor states, with monthly Census Building Permits Survey (BPS) data from Nov 2019–Oct 2025. The TWFE estimate is positive but imprecise; the synthetic control estimate is essentially zero with placebo-based p≈0.96. The paper emphasizes that pre-trends and aggregation make credible identification difficult.

For a top journal, the current manuscript does **not** deliver credible causal identification nor a compelling methodological contribution beyond a cautionary tale, and it uses an outcome measure that is poorly aligned with the policy margin (ADUs/duplexes). I would not recommend publication in its current form.

---

# 1. FORMAT CHECK

### Length
- Total PDF appears to be **~36 pages** including figures, references, and appendix (page numbers shown up to 36).
- Main text runs roughly **pp. 5–31 (~27 pages)**, which *meets* the “≥25 pages excluding references/appendix” bar.

### References
- Bibliography includes major classic housing supply/regulation references (Glaeser & Gyourko; Saiz; Hsieh & Moretti) and core DiD/SCM citations (Callaway–Sant’Anna; Goodman-Bacon; Sun–Abraham; Abadie–Diamond–Hainmueller; Arkhangelsky et al.).
- However, the policy and empirical upzoning/ADU literature coverage is **thin and dated**, and key modern synthetic control/inference and “pre-trend sensitivity” references are missing (details in Section 4).

### Prose (bullets vs paragraphs)
- Major sections (Intro, Literature, Results, Discussion) are in paragraph form. **PASS.**

### Section depth (3+ substantive paragraphs each)
- **Introduction (Section 1)**: multiple paragraphs. **PASS.**
- **Policy background (Section 2)**: multiple paragraphs in each subsection. **PASS.**
- **Literature review (Section 3)**: multiple paragraphs. **PASS**, though it is heavy on broad citations and light on closely related empirical work.
- **Results (Section 5)**: several subsections are quite short; e.g., visual evidence + some robustness discussion read like short summaries rather than fully developed interpretation. Borderline but acceptable.
- **Discussion (Section 6)**: multiple paragraphs; reasonably structured. **PASS.**

### Figures
- Figures shown (Montana vs controls; event study; synthetic control; placebo distribution) have visible data and labeled axes. **PASS**, but:
  - Event-study figure (Fig. 2) needs clearer axis labels/units and a statement of binning (quarters) and reference period *in the caption* (partly present).
  - Placebo distribution (Fig. 5) looks publication-rough; the state labels are difficult to read at journal resolution.

### Tables
- Tables contain real numbers and report standard elements (coefficients, SEs, CIs, N). **PASS.**
- Some tables need clearer definitions:
  - Table 1 (“Total Permits”) is ambiguous: is that *mean monthly permits*? If so, label as such. If it is a sum over the period, then the magnitudes look inconsistent with N.

### Serious presentational / production issues
- The PDF text has repeated encoding artifacts (“pro￾vides”, “statistically insignif￾vides”), which is unacceptable for a top journal submission.
- Multiple in-text citations are placeholders **“(?)”** (e.g., Section 6.1 and other locations). This is a hard **format/content fail**: it signals incomplete scholarship and prevents verification.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard Errors
- Main regression tables report **SEs in parentheses** (e.g., Table 2, Table 3, Table 4). **PASS.**

### b) Significance Testing
- p-values are reported (clustered p-values and wild bootstrap p-values in Table 2; p-values elsewhere). **PASS.**

### c) Confidence Intervals
- Table 2 reports **95% CI** in brackets. **PASS.**

### d) Sample Sizes
- N is reported in Tables 2–3 (N=432). **PASS.**
- Make sure **every** regression table includes N (Table 4 currently does not show N—add it).

### e) DiD with staggered adoption
- This is a **single treated unit** with a common start date; no staggered-adoption bias from “already-treated as controls.” **PASS** on this specific criterion.
- However, single-treated-unit DiD has well-known inference/identification fragility; see below.

### f) RDD
- Not applicable.

### Bottom line on “publishability” from an inference standpoint
The paper **does not fail** on the mechanical inference reporting requirements. However, for top-journal standards, the bigger problem is that the econometrics are not *credible for causal inference given the design and measurement*, and the paper’s own event study indicates pre-trend violations.

---

# 3. IDENTIFICATION STRATEGY

### Core identification claim
The paper’s identification rests on: absent reform, Montana’s state-level per-capita permits would have tracked (i) an average of five selected controls (TWFE DiD) or (ii) a weighted combination of donor states (SCM).

### Why identification is currently not credible (and the paper partly admits this)
1. **Pre-trends / non-parallel trends (Section 5.5, Fig. 2, p. ~21–22)**  
   - The event study shows sizable relative movements pre-treatment. This undermines DiD’s identifying assumption.
   - The manuscript treats this as “problematic pre-trends” but then still reports a TWFE estimate as if it were meaningful. In a top journal, this must be handled more formally (e.g., sensitivity to deviations from parallel trends, restrictions on pre-period fit, alternative designs).

2. **Treatment is not “statewide” in exposure (despite statewide legislation)**  
   - SB323 applies only to municipalities above population thresholds (and county thresholds). State-level aggregation **dilutes** treatment intensity and creates an unknown first-stage: the fraction of housing market subject to duplex upzoning varies across states and over time.
   - This is not a minor limitation; it is a fundamental mismatch between policy and outcome unit.

3. **Outcome mismeasurement relative to policy margin (BPS categories)**  
   - ADUs are not cleanly identified in BPS structure counts. Detached ADUs can appear as “1-unit structures,” while attached ADUs may appear as “2-unit structures,” and many ADUs are created via conversions/additions that may not appear as new “units authorized” in the same way.
   - Your heterogeneity splits “single-family vs multi-family” (Table 3), but the reform’s most direct mechanical prediction is on **2-unit** permits and possibly “1-unit” (detached ADUs). Collapsing everything into “multi-family” (which includes 3–4 and 5+) is noisy and arguably not policy-relevant.

4. **Legal injunction creates ambiguous treatment timing (Section 2.3; Table 4)**  
   - You treat Jan 2024 as onset but acknowledge legal uncertainty until March 2025. This is effectively a two-stage/partial-compliance setting.
   - The “March 2025 treatment” robustness check uses only ~8 post months; it is not persuasive and is highly sensitive to short-run noise.

5. **Synthetic control pre-fit is weak (Table 5, RMSPE ≈ 10 on a mean ≈ 40)**  
   - A pre-RMSPE of ~10 permits/100k is large; the SCM counterfactual may not be credible.
   - Donor weights include far-away states (e.g., SC, RI). That is not inherently invalid, but it raises questions about whether the match is coming from idiosyncratic volatility rather than shared determinants. You need more structure in predictors and/or alternative SCM variants.

### Placebos and robustness
- Placebo tests in SCM are a **strength**, but the implementation needs tightening:
  - Clarify whether the p-value is one-sided or two-sided and justify based on the estimand (you expect nonnegative supply response, so two-sided is conservative but should be explicit).
  - Standard practice is to restrict placebo set to units with comparable pre-fit (you mention excluding top 10% pre-RMSPE in Fig. 5 notes). This should be systematically reported and sensitivity-checked.

### Do conclusions follow?
- The paper’s conclusion (“credible identification is not achieved with available data”) is actually the most defensible part. But that conclusion implies the paper is **not an evaluation** so much as a demonstration of inadequacy of state-level designs for this question. A top journal would require either:
  1) a credible alternative design/data that *does* identify effects, or  
  2) a methodological contribution that generalizes beyond this single case.

At present, it is neither.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology literature missing / underused
You cite many key DiD papers, but you should add and engage with:

1. **Pre-trend sensitivity / “Honest DiD”**  
Why: Your event study shows pre-trend problems; modern practice is to quantify sensitivity rather than just note it.
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

2. **Augmented synthetic control (reduces bias, improves fit)**  
Why: Your SCM pre-fit is mediocre; augmented SCM is now standard in many applied SCM papers.
```bibtex
@article{BenMichaelFellerRothstein2021,
  author  = {Ben-Michael, Eli and Feller, Avi and Rothstein, Jesse},
  title   = {The Augmented Synthetic Control Method},
  journal = {Journal of the American Statistical Association},
  year    = {2021},
  volume  = {116},
  number  = {536},
  pages   = {1789--1803}
}
```

3. **Wild cluster bootstrap refinements for few clusters**  
Why: With 6 clusters, you should cite modern guidance beyond Cameron–Gelbach–Miller (2008), and report implementation details.
```bibtex
@article{MacKinnonWebb2017,
  author  = {MacKinnon, James G. and Webb, Matthew D.},
  title   = {Wild Bootstrap Inference for Wildly Different Cluster Sizes},
  journal = {Journal of Applied Econometrics},
  year    = {2017},
  volume  = {32},
  number  = {2},
  pages   = {233--254}
}
```

### Empirical zoning / upzoning literature missing
You cite Auckland (Greenaway-McGrevy & Phillips) and some descriptive US work, but for credibility you need to position relative to US quasi-experimental upzoning evidence. One key example:

```bibtex
@article{Freemark2020,
  author  = {Freemark, Yonah},
  title   = {Upzoning Chicago: Impacts on Land Values and Housing Construction},
  journal = {Urban Affairs Review},
  year    = {2020},
  volume  = {56},
  number  = {3},
  pages   = {758--789}
}
```

(If you are aware of more recent causal evaluations of state ADU laws or duplex legalization, those must be added; currently the review leans heavily on policy reports and broad theory.)

### Internal citation completeness
- Replace all “(?)” placeholders with specific citations. A top journal will desk-reject a manuscript with missing citations and unresolved reference markers.

---

# 5. WRITING AND PRESENTATION

### Clarity and structure
- The manuscript is generally well organized (policy background → data/methods → results → discussion). The abstract is clear and appropriately cautious.
- However, there is a tension: the title and framing promise an evaluation of “effects,” but the paper ultimately argues effects are not identified. That mismatch weakens the contribution.

### Technical presentation issues (must fix)
- Encoding/ligature artifacts throughout.
- Missing citations (“(?)”).
- Some claims lack sourcing (e.g., national price growth statistics in the intro).
- SCM description and donor exclusions are not fully transparent (which “major reforms” qualify? Why only CA/OR/ME?).

### Figures/tables publication quality
- Figures are readable in the draft but not yet journal-grade (especially placebo distribution). Improve labeling, fonts, and add notes about units and construction.

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make this publishable)

To have a serious chance at a top journal, you likely need **a different research design and/or different data**. Concretely:

1. **Move from state-level to place-level (city/permit-issuing jurisdiction)**
   - Use BPS place-level files (restricted if necessary) or administrative permit microdata from Montana municipalities.
   - Exploit SB323 eligibility thresholds (city pop > 5,000 and county pop > 70,000) in a **difference-in-differences-in-differences** or **difference-in-discontinuities** framework:
     - Treated: eligible cities in MT
     - Controls: ineligible MT cities + eligible cities in control states (or eligible vs near-eligible within MT)
   - This is the single most important fix: it aligns unit of observation with policy exposure and dramatically improves identification.

2. **Target outcomes that map to the reform**
   - Separate 2-unit permits explicitly (duplex channel).
   - Attempt to identify ADUs using local permit codes, assessor records, or inspections data; BPS alone is not adequate.

3. **Model partial compliance / legal uncertainty explicitly**
   - Treat injunction period as “blocked treatment” or “imperfect treatment” and estimate an intention-to-treat vs treatment-on-the-treated style effect using legal status as an instrument (if you can measure actual enforcement/ordinance updates).

4. **Address pre-trends formally**
   - Implement **Rambachan–Roth** sensitivity analysis (HonestDiD) to quantify how large violations must be to overturn conclusions.
   - Consider restricting to a pre-period with better fit or using detrending with explicit justification (but beware mechanical overfitting).

5. **Upgrade SCM implementation**
   - Use augmented SCM and report sensitivity to predictor sets and donor pool restrictions.
   - Report donor pool screening rules (exclude other states with ADU/duplex preemption during sample).
   - Provide leave-one-out weight stability checks.

6. **Power and detectable effects**
   - With one treated state and volatile monthly permits, a simple minimum-detectable-effect calculation would help interpret null results. If the design is underpowered, say so clearly and adjust claims accordingly.

7. **Reframe contribution**
   - If you cannot obtain place-level data, a more honest contribution is a *methods/policy-evaluation note* about why state-level BPS cannot identify ADU/duplex reforms. But that is unlikely to clear AER/QJE without a broader methodological innovation.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Transparent presentation of TWFE DiD and SCM side-by-side.
- Correctly cautious interpretation; the paper does not overclaim and explicitly flags pre-trend concerns.
- Use of permutation/placebo inference for SCM and wild bootstrap p-values is directionally appropriate with few clusters.

### Critical weaknesses (fatal for a top journal in current form)
- **Identification is not credible** at the state level given partial exposure, outcome mismeasurement, and pre-trend violations.
- The paper effectively concludes “we cannot identify effects,” which is not sufficient as a top-journal contribution absent new data or a generalizable methodological advance.
- SCM pre-fit is weak and donor selection/exclusion criteria are under-justified.
- Manuscript is not submission-ready due to encoding artifacts and unresolved citations (“(?)”).

---

## VERDICT: REJECT

The paper is careful and in places self-critical, but for AER/QJE/Econometrica standards it lacks a credible identification strategy and an outcome aligned with the policy margin. The path forward is a major redesign using place-level data and threshold-based within-/near-within-state variation; without that, the study is unlikely to become publishable in a top journal.